- Dosing & Administration
- STR Pill Guide
- Treatment Scenarios
- Test Your Knowledge
- Efficacy & Resistance
- Tolerability & Safety
- Treatment Resources
The Protective Barrier to Resistance of Darunavir in a Convenient STR1
Dosing & Administration
One tablet, once daily with food.
Not Actual Size
The smallest darunavir coformulation available.
SYMTUZA® is a complete regimen that is smaller than PREZCOBIX®.
If desired, patients have the option to split the pill into 2 pieces. The whole dose should be taken immediately after splitting. When splitting SYMTUZA®, a standard tablet splitter may be used.
SYMTUZA® is a 4-drug fixed-dose combination product containing 800 mg of darunavir (DRV), 150 mg of cobicistat (COBI), 200 mg of emtricitabine (FTC), and 10 mg of tenofovir alafenamide (TAF).
The recommended dosage of SYMTUZA® is 1 tablet taken orally once daily with food in adults and pediatric patients weighing at least 40 kg. For patients who are unable to swallow the whole tablet, SYMTUZA® may be split into 2 pieces using a tablet splitter, and the entire dose should be consumed immediately after splitting.
Not Recommended in Patients With Severe Renal Impairment
SYMTUZA® is not recommended in patients with creatinine clearance below 30 mL per minute.
Not Recommended During Pregnancy
SYMTUZA® is not recommended during pregnancy because of substantially lower exposures of darunavir and cobicistat during the second and third trimesters.
SYMTUZA® should not be initiated in pregnant individuals. An alternative regimen is recommended for those who become pregnant during therapy with SYMTUZA®.
Testing Prior to Initiation of SYMTUZA®
Prior to or when initiating SYMTUZA®, and during treatment with SYMTUZA®, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.
Not Recommended in Patients With Severe Hepatic Impairment
SYMTUZA® is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).
Not Recommended in Pediatric Patients Weighing <40 kg
The safety and effectiveness of SYMTUZA® have not been established and is not recommended in pediatric patients weighing less than 40 kg.
The Centers for Disease Control and Prevention recommends that HIV-infected mothers in the United States must not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection.
DOSAGE FORMS AND STRENGTHS
Each SYMTUZA® tablet contains darunavir ethanolate equivalent to 800 mg of darunavir, 150 mg of cobicistat, 200 mg of emtricitabine (FTC), and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide (TAF). The yellow to yellowish-brown capsule-shaped, film-coated tablet is debosed with "8121" on one side and "JG" on other side.
Drugs that are contraindicated
|Alpha 1-adrenoreceptor agonist||alfuzosin|
|Anticonvulsants||carbamazepine, phenobarbital, phenytoin|
|Anti-gout||colchicine in patients with renalor hepatic impairment|
|Cardiac disorders||dronedarone, ivabradine, ranolazine|
|Ergot derivatives||dihydroergotamine, ergotamine, methylergonovine|
|GI motility agent||cisapride|
|Hepatitis C direct-acting antivirals||elbasvir/grazoprevir|
||lomitapide, lovastatin, simvastatin|
|PDE-5 inhibitor||sildenafil for treatment of pulmonary arterial hypertension|
|Sedative/hypnotics||midazolam (oral), triazolam|
Coadministration not recommended*
|Systemic/inhaled/nasal/ophthalmic corticosteroids||betamethasone, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, mometasone, triamcinolone|
|Hepatitis C direct-acting antivirals||glecaprevir/pibrentasvir|
|Inhaled beta agonist||salmeterol|
|Platelet aggregation inhibitors||clopidogrel, ticagrelor|
*Recommendations are based on drug interaction trials conducted with components of SYMTUZA®, as individual agents or in combination, or are predicted interactions.
GI=gastrointestinal; PDE-5=phosphodiesterase type 5; STR=single-tablet regimen.
Reference: 1. SYMTUZA® [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP.